Journament

Keyword Connections - bevacizumab Keywords

Connection Type	Connection
Journals	japanese journal of clinical oncology Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners journal of community hospital internal medicine perspectives science (new york, ny) gynecologie, obstetrique, fertilite & senologie translational lung cancer research
Research Groups	No Research Group Connected
Bibliographies	[1] [Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. [2] Pharmaceutical diversification via palladium oxidative addition complexes. [3] A severe case of bevacizumab-induced thrombotic microangiopathy. [4] Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer. [5] Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study. [6] Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. [7] Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab [8] all india ophthalmological society members' survey: practice pattern of intravitreal anti-vascular endothelial growth factor injection [9] spectral domain optical coherence tomography morphology in optic disc pit associated maculopathy [10] loop myopexy with true muscle transplantation for very large angle heavy eye syndrome patient [11] shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma [12] use of a combination of Аvastin and low-dose interferon- α in the first-line treatment of metastatic renal-cell cancer [13] combined special capsular tension ring and toric iol implantation for management of post-dalk high regular astigmatism with subluxated traumatic cataract [14] erratum: how to make the ghosts in my bedroom disappear? focused-attention meditation combined with muscle relaxation (mr therapy) — a direct treatment intervention for sleep paralysis [15] circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens [16] utilización del bevacizumab en la neovascularización corneal use of bevacizumab in corneal neovascularization [17] metastatic renal cell carcinoma: a guide to therapy based on current evidence [18] an unusual case of self-inflicted multiple needles injuries to eye [19] immediate sequential bilateral intravitreal injections: an indian perspective [20] spectral domain optical coherence tomography features of multiple subfoveal retinal pigment epithelial tears after intravitreal bevacizumab [21] Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. [22] Evaluation of the Effect of Repeated Intravitreal Bevacizumab Injections on the Macular Microvasculature of a Diabetic Patient Using Optical Coherence Tomography Angiography [23] A severe case of bevacizumab-induced thrombotic microangiopathy. [24] Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature [25] [Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312 mg Bevacizumab]. [26] [Bevacizumab and invasive procedures: practical recommendations]. [27] Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. [28] A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). [29] Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer. [30] Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study. [31] The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. [32] Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia [33] Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. [34] Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab [35] Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration as First Choice: a New Italian Ruling [36] Dramatic Resolution of Recalcitrant Cystoid Macular Edema after Concurrent Intravitreal Injection of Bevacizumab and Triamcinolone [37] intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration ranibizumab e bevacizumab intravítreo no tratamento da neovascularização de coróide extrafoveal da degeneração macular relacionada à idade [38] intravitreal bevacizumab in aggressive posterior retinopathy of prematurity [39] treatment of corneal neovascularization using anti-vegf bevacizumab [40] intravitreal bevacizumab in nonarteritic anterior ischemic optic neuropathy [41] diabetic papillopathy with macular edema treated with intravitreal bevacizumab [42] bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle [43] new prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer [44] use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics injeção intravítrea de bevacizumabe ou triancinolona como adjuvantes da vitrectomia posterior no tratamento da hemorragia vítrea em diabéticos [45] bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern [46] photopsias during systemic bevacizumab therapy [47] shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma [48] retro-mode imaging of fibrovascular membrane in proliferative diabetic retinopathy after intravitreal bevacizumab injection [49] sd-oct morphological changes in wet age-related macular degeneration patients after bevacizumab treatment [50] a comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (macugen), ranibizumab (lucentis) and bevacizumab (avastin) [51] successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye [52] circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens [53] antiproliferative, apoptotic, and autophagic activity of ranibizumab, bevacizumab, pegaptanib, and aflibercept on fibroblasts: implication for choroidal neovascularization [54] cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial [55] utilización del bevacizumab en la neovascularización corneal use of bevacizumab in corneal neovascularization [56] conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab [57] bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel [58] rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography [59] bevacizumab for advanced ovarian cancer treatment. a grade based approach [60] a case report of long term bevacizumab treatment in multiresistant ovarian cancer [61] current status of bevacizumab in advanced ovarian cancer [62] spectral domain optical coherence tomography features of multiple subfoveal retinal pigment epithelial tears after intravitreal bevacizumab [63] intravitreal bevacizumab (avastin) for the treatment of proliferative sickle retinopathy [64] takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer [65] Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?